online ISSN 2415-3176
print ISSN 1609-6371
logoExperimental and Clinical Physiology and Biochemistry
  • 3 of 12
Up
ECPB 2019, 87(3): 23–29
https://doi.org/10.25040/ecpb2019.03.023
Research articles

Effect of Fluoroquinolones on the Activity of the Glutathione System in the Peripheral Blood Lymphocytes

І.V. KOVALENKO, О.К. ONUFROVYCH, О.V. MELNYK, O.S. KORCHYNSKA, N.M. VOROBETS, Z.D. VOROBETS
Abstract

An important role in the etiotropic therapy of purulent-inflammatory complications take fluoroquinolones which are active against pathogenic microflora. Due to their wide range of antimicrobial activity, low toxicity, good pharmacokinetics properties, they are widely using in the treatment of bacterial infections of different localization. These are drugs of ultra-wide range of activity, active against gram-positive and gram-negative, aerobic and anaerobic microorganisms, chlamydia, mycoplasma, mycobacteria.

It is possible to assume that a number of antibiotics fluoroquinolone if it enters in a human body also act on eukaryotic cells, in particular blood cells. It is considered that lymphocytes of peripheral blood are the "metabolic mirror" of organism, and, consequently, can serve as a model for the study of influence of fluoroquinolones on the metabolic and regulatory systems of cells. The purpose of this work was a study the effect of a number of fluoroquinolones on lipid peroxidation and the activity of the glutathione antioxidant blood lymphocyte system. The object of research was the blood of practically healthy women.

We carried out a comparative study of the processes of lypoperoxidation and glutathione system in peripheral blood lymphocytes under the influence of fluoroquinolones of II – IV generations. In all cases, the activation of LРО processes is shown, by determining the concentration of malondialdehyde, which is a secondary product of lipid peroxidation. Thus, in the blood lymphocytes of the control group, the concentration of MDA is (4.1 ± 0.4) μmol/l. With the action of ciprofloxacin (II generation), the processes of GHI are intensified 1.7 times relative to the parameters in the control group, with the MDA concentration reaching (6.6 ± 0.5) μmol/l (p < 0.001). When exposed to cells levofloxacin (third generation) processes more activated LPO, MDA concentration increases to 7,4 ± 0,6) mmol/L, that is about 1.8 times to control values. A similar situation is observed when determining the concentration of MDA in blood lymphocytes under the action of moxifloxacin (IV generation). Moxifloxacin resulted in a 1.9-fold increase in MDA to 7.9 ± 0.7 μmol / l (p < 0.001).

The activity of glutathione peroxidase lymphocytes under the action of ciprofloxacin increased from 154.2 ± 13.4 nmol GSН/min ∙ mg protein (control) to 177.3 ± 13.7 (p > 0.05), when exposed to levofloxacin – to 190.3 ± 10.7 (p < 0.05), and when exposed to moxifloxacin – up to 199.3 ± 14.7 nmol GSH / min ∙ mg protein (p < 0.05). That is, a significant increase in the activity of glutathione peroxidase occurs only under the action of moxifloxacin, 1.3 times. Regarding the activity of glutathione reductase, in lymphocytes in control it was 51.7 ± 4.2 nmol NADPH/min ∙ mg protein. With ciprofloxacin, it decreased to 40.7 ± 4.2 (p > 0.05), levofloxacin – to 40.1 ± 4.2 (p > 0.05), and with moxifloxacin – to 37.9 ± 3.1 nmol NADPH/min ∙ mg protein. Glutathione S-transferase activity in lymphocytes in control was 112.2 ± 9.2 nmol GSH/min ∙ mg protein. With ciprofloxacin, it increased 2.3 (p < 0.001), levofloxacin 3.1 (p < 0.001), and moxifloxacin 3.8 times (p < 0.001).

We presume that fluoroquinolones activate the processes of lipid peroxidation in blood lymphocytes. Fluoroquinolones do not affect the concentration of reduced glutathione in blood lymphocytes, but they do increase the activity of glutathione peroxidase and glutathione S-transferase.

Received: 05.09.2019

Keywords: fluoroquinolones, lymphocytes, lipid peroxidation, glutathione peroxidase, glutathione reductase, glutathione S-transferase

Full text: PDF (Eng) 488K

References
  1. 1. Almakaeva LG, Begunova NV, Naumenok LG, Dolya VG, Almakaev МS. Development of composition of infusion medication on basis of moxifloxacin. Annals of Mechnikov Institute. 2015;2:70-3 (in Ukrainian).
  2. 2. Dudikova ML, Vrynchanu NO, Dronova ML. New antibiotics of the quinolone series: prospects for use in medical practice. Pharmacology and Medical Toxicology. 2015;1(432), 3-12 (in Ukrainian).
  3. 3. Ferrandiz MJ, Martin-Galiano AJ, Arnanz C, Zimmerman T, de la Campa AG. Reactive oxygen species contribute to the bactericidal effects of the fluoroquinolone moxifloxacin in Streptococcus pneumonia. Antimicrobial Agents and Chemotherapy. 2016;60(1):409-17. doi.org/10.1128/AAC.02299-15
  4. 4. Paliy GK, Nazarchuk OA, Nahajchuk VI, Osadchuk NI, Paliy DV, Kovalenko IV. Analytic prognostication of sensitivity of staphilococcus to fluoroquinolones. Svit Medicini i Biologii. 2015;3(51):103-6 (in Ukrainian).
  5. 5. Ambulkar PS, Ghosh SK, Indole IV, Pal AK. Genotoxic and cytotoxic effects of antibacterial drug, ciprofloxacin, on human lymphocytes in vitro. Nepal Medical College Journal. 2009;11(3):147-51.
  6. 6. Kanyuka O, Paul O. Future use flioroquinolone generation in treatment bacterial infections. Nauk. Visnyk S. Gzhytskoho LNUVMBT. 2011;2(48): 107-11 (in Ukrainian).
  7. 7. Chatzika K, Manika K, Kontou P, Pitsiou G, Papakosta D, Zarogoulidis K, Kioumis I. Moxifloxacin pharmacokinetics and pleural fluid penetration in patients with pleural effusion. Antimicrobial Agents and Chemotherapy. 2014; 58(3):1315-9. doi.org/10.1128/AAC.02291-13
  8. 8. Demchuk HV. Estimation of safety of fluoroquinolones for therapy of community- acquired pneumonia of the patients with diabetes mellitus. Visnyk Vinnytskoho Mededychnogo Univiversitetu. 2014;18(2):525-8 (in Ukrainian).
  9. 9. Coskun D, Parlak K, Dik B, Faki HE, Bahcivan E, Yazar E, Er A. Effect of enrofloxacin on the fluid/blood oxidative status and organ damage markers. Annual Research & Review in Biology. 2018;25(3):1-7. doi.org/10.9734/ARRB/2018/40537
  10. 10. Potjo, M., Cockeran, R., Theron, A.J., Feldman, C. & Anderson, R. Effect of moxifloxacin on human neutrophil and T-lymphocyte functions in vitro. Pharmaceuticals. 2010; 3: 3570-80. doi.org/10.3390/ph3123570
  11. 11. Riesbeck, K. Immunomodulating activity of quinolones: review. Journal of Сhemotherapy. 2002;14(1):3-12. doi.org/10.1179/joc.2002.14.1.3
  12. 12. Fafula RV, Iefremova UP, Luchkovska NE, Vorobets ZD, Kulachkovskii OR. Methodological approach to the study of the enzymatic spectrum of lymphocytes at pathological states using a detergent of saponin (ultrastructural study). Visnyk Problem Biologii i Medecini. 2012;1(96):163-6 (in Ukrainian).
  13. 13. Birben E, Sahiner MU, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012;5(1):9-19. doi.org/10.1097/WOX.0b013e3182439613
  14. 14. Gautam N, Das S, Mahapatra SK, Chakraborty SP, Kundu PK, Roy S. Age associated oxidative damage in lymphocytes. Oxid. Med. Cell Longev. 2010;3(4):275-82. doi.org/10.4161/oxim.3.4.12860
  15. 15. Anderson ME. Determination of glutathione and glutathione disulfide in biological samples. Methods in Enzymology. 1985;113:548-55. doi.org/10.1016/S0076-6879(85)13073-9
  16. 16. Beberok A, Wrzesniok D, Otreba M, Milinski M, Rok J, Buszman E. Effect of norfloxacin and mixifloxacin on melanin synthesis and antioxidant enzymes activity in normal human melanocytes. Mol. Cell. Biochem. 2015;401:107-14. doi.org/10.1007/s11010-014-2297-7
  17. 17. Ore A, Olayinka ET. Influence of moxifloxacin on hepatic redox status and plasma biomarkers of hepatotoxicity and nephrotoxicity in rat. Biochemistry Research International. 2015;15:1-8. doi.org/10.1155/2015/192724
  18. 18. Kumbhar GB, Khan AM, Rampal S. Evaluation of gatifloxacin for its potential to induce antioxidant imbalance and retinopathy in rabbits. Human & Experimental Toxicology. 2014;34(4):372-9. doi.org/10.1177/0960327114530743


Програмування - Roman.im